NCT07305298Not yet recruiting
Mirabegron in Patients With Age-Related Macular Degeneration
Mirabegron in Patients With Age-Related Macular Degeneration Treated for Overactive Bladder: A Study Protocol for a Non-Randomized Prospective Controlled Trial
Source: ClinicalTrials.gov · Last updated 6 Feb 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if Mirabegron works to treat dry AMD in patients, aged between 50 and 80 years-old, with early or moderate dry AMD and overactive bladder. The main question it aims to answer is: • Is there any change in outer retina morphology in patients treated? Researchers will compare the safety and efficacy of mirabegron versus conventional approach (Solifenacin) to treat dry AMD in patients with dry AMD and overactive bladder. Participants will: * Take Mirabegron or Solifenacin every day for 12 months * Visit the clinic once every 6 months for checkups and tests
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 312 (estimated)
- First submitted
- 27 Nov 2025
- Start date
- 1 Apr 2026
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- University of Naples
- Diseases
- Macular degeneration
- NCT number
- NCT07305298
What you commit to
- Study type: Observational
- Planned participants: 312
- From 1 Apr 2026 to the primary completion date, 1 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- • Any medical condition which contraindicates the use of beta-agonists
- Uncontrolled hypertension
- Tachycardia or atrial fibrillation
- Any allergies to the beta-agonists
- Renal or hepatic failure
- Long QT or concomitant treatment with drugs that cause lengthening of the QT interval
- Any sign of ocular inflammation
- xudative AMD
- Any ongoing medical or surgical treatment for AMD (including intravitreal injections, oral supplementation of lutein, zeaxanthin and or high dietary intake of antioxidants)
- Any other ophthalmic diseases such glaucoma, acute or chronic uveitis, advanced cataract, or any opacities of the ocular media that do not permit high-quality imaging examinations.
- Pregnancy
- Any condition or disease that in the opinion of the investigators may put the subject at significant risk or may interfere significantly with the subject's participation in the study (i. e. malignancy, uncontrolled or cardiovascular diseases)
Who the study is looking for
- Age subjects 50 and 80 years-old
- Ability to express informed consent
- Early or moderate dry AMD according to ARDS classification
- Overreactive bladder
- Visual acuity greater than BCVA 65 EDTRS letters.
Age in the registry: 50 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Federico II Coordinator of this site? Confirm its status | Naples | Italy | Unknown status |
Related publications
- Mirabegron in patients with age-related macular degeneration treated for overactive bladder: a study protocol for a prospective observational non-randomized trial.Front Med (Lausanne) · 2026 · PMID 41919172
This page is information, not medical advice. Discuss any trial with your doctor.